

15th Annual Conference of Chinese Biopharmaceutical Association, USA

USM Shady Grove Center
9636 Gudelsky Drive, Building 2
Rockville, Maryland 20850 USA

Biopharmaceutical Medicines: Development and Commercialization without Borders

PROGRAM

Friday, June 11, 2010

Cocktail and Dinner Reception for Speakers and VIP Sponsors
6:00 PM – 9:00 PM
The Cosmos Club, 2121 Massachusetts Avenue, NW, Washington, DC

Saturday, June 12, 2010

Registration, Continental Breakfast, Exhibition

7:30 AM – 9:00 AM Continental Breakfast, Coffee and Tea
8:00 AM – 9:00 AM Registration and Exhibition
9:00 AM – 9:05 AM Welcome Remarks: Dr. Yifan Zhai, President of CBA

Opening Remarks

9:05 AM – 9:15 AM Minister GuangYuan Liu, Embassy of the People’s Republic of China in the USA
9:15 AM – 9:25 AM Mr. John P. McDonough, Secretary of State, Maryland, USA

Plenary Session and CBA’s Brilliant Achievement Award Presentations

9:25 AM – 9:30 AM Introduction of the Brilliant Achievement Awardees by Dr. Sujuan Ba, President-Elect of CBA
9:30 AM – 10:00 AM

Fulfilling the Promise of a Sequenced Human Genome

Dr. Eric Green, Director, National Human Genome Research Institute, National Institutes of Health

10:00 AM – 10:30 AM

Developing and Commercializing Personalized Medicines Beyond “Borders”

Mr. Gabriel Leung, President, Pharmaceuticals Business, OSI Pharmaceuticals

Break & Refreshments

10:30 AM – 10:45 AM

Session 1

An Insider's View of the Current State of Biopharmaceutical Development and Commercialization
(Presentations and Panel Discussion)

Session Chairs: Dr. Dajun Yang and Dr. Zhifeng Long

10:45 AM – 11:05 AM

Building a Bioscience Economy in Luxembourg

Mr. Gerald McDougall, Partner, Health Science Practice, PricewaterhouseCoopers, LLP

11:05 AM – 11:25 AM

National Drug Policy Research and the Development of China's Pharmaceutical Industry on Health Care Reform

Mr. Ruilin Song, Executive President, China Pharmaceutical Industry Research and Development Association (Sino-PhIRDA)

11:25 AM – 11:45 AM

Facilitating Cancer Research through Applications of Genomic Technologies

Dr. Robert Strausberg, Director of Collaborative Sciences, Ludwig Institute for Cancer Research

Session 2A

An Emerging Center for Biopharmaceutical R&D – Showcasing China's Biotech Parks and Partnering Opportunities (Presentations and Panel Discussion)

Session Chairs: Dr. Yifan Zhai and Dr. Shoupeng Lai

11:45 AM – 12:05 PM

Leveraging China's Resources for the Advancement of Biotechnology

Dr. Guo-Liang Yu, Chairman and CEO, Epitomics, Inc.

12:05 PM – 12:25 PM

The Investment Environment for the Bio-Pharmaceutical Industry in Suzhou Wuzhong District

Mr. Xingnan Yu, Director of the People's Government of Suzhou Wuzhong District

12:25 PM – 12:35 PM

China Medical City Overview

Dr. Lin Sun-Hoffman, President, Sun-Hoffman Consulting, Representative for CMC

12:35 PM – 12:45 PM

Overview of SCCIP

Dr. Patrick Lu, Executive Vice Director, SCCIP

Break for Lunch, Exhibitions, Job Fairs, and Networking

12:45 PM – 2:00 PM

Keynote Presentation

2:00 PM – 2:05 PM Introduction by Dr. Richard Zhao

2:05 PM – 2:35 PM

Functionalizing the Cancer Genome

Dr. Lynda Chin: Professor of Dermatology, Harvard Medical School, Scientific Director, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School and Broad Institute of MIT and Harvard

Session 2B (Concurrent in Separate Meeting Rooms)

2:35 PM – 4:15 PM and 4:30 PM – 5:15 PM

Face-to-face partnering meetings between P&D projects and China's Biotech Parks

Session 3:

Novel Therapeutics and Companion Diagnostics (Presentations and Panel Discussion)

Session Chairs: Dr. Edward Wang and Dr. Richard Zhao

2:35 PM – 2:55 PM

Personalized Medicine and Companion Diagnostics – Regulatory Considerations

Dr. Živana Težak, Associate Director for Science and Technology, Personalized Medicine/OIVD/CDRH/FDA

2:55 PM – 3:15 PM

Developing Molecular Targeted Therapy for Cancer – Global Approach for Global Disease

Dr. Li Yan, Director, Clinical Oncology, Merck & Co., Inc.

3:15 PM – 3:35 PM

Nanomedicines: Improving Current Therapies and Diagnosis

Dr. Esther Chang, Professor of Oncology and Otolaryngology, Georgetown University

3:35 PM – 3:55 PM

Novel Molecular Biomarkers in Diagnosis and Early Detection

Dr. Wendy Wang, Program Director, Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute

Break & Refreshments

3:55 PM – 4:10 PM

Session 4

The Regulatory Landscape for Biosimilars (Presentations and Panel Discussion)

Session Chairs: Dr. Yanni Wang and Dr. Li Li

4:10 PM – 4:30 PM

Factors for Consideration in Assessing Comparability of Follow-on Protein Products

Dr. Andrew Chang, Executive Director, PharmaNet Consulting, PharmaNet Development Group, Inc.

4:30 PM – 4:50 PM

Regulatory Pathways for Follow-on Biologics in Asia

Dr. Chih-hwa Wallace Lin, Director, Division of Resource Development, Center for Drug Evaluation Taiwan

4:50 PM – 5:10 PM

An Overview of Regulatory and Scientific Issues for Biosimilars and Follow-on Biologics

Dr. Duu-Gong Wu, Executive Director, Consulting Division, PharmaNet, Inc.

5:10 PM – 5:30 PM

Panel Discussion

Cocktail Reception

5:30 PM – 7:00 PM

In the Exhibit Room

Evening Session and Dinner Banquet

In the Main Conference Room

7:00 PM – 9:00 PM

Masters of Ceremony: Dr. Patrick Yu, Dr. Yali Fu, Ms. Beth Wong, and Dr. Yingxian Xiao

2010 CBA Outstanding Service Award and Presentation

2011 CBA President – Election Announcement and Statement

Raffle Prize Drawings

Sunday, June 13, 2010

Breakfast and Registration

7:30 AM – 9:00 AM

Keynote Presentation

9:00 AM – 9:05 AM Introduction by Dr. Yuling Li

9:05 AM – 9:35 AM

Current Challenges and Opportunities for Biologics Drug Discovery and Development

Dr. Herren Wu, Vice President, Head of Antibody Discovery and Protein Engineering, MedImmune

Session 5

Stem Cells: From Metabolic Syndrome to Cancer (Presentation and Panel Discussion)

Session Chairs: Dr. Bin Gao and Dr. Yuling Li

9:35 AM – 9:55AM

Human Pluripotent Stem Cells: Disease Modeling and Treatment

Dr. Linzhao Chen, Associate Professor, Johns Hopkins University

9:55 AM – 10:15AM

The Sirtuin Deacetylases, the Longevity Gene, Metabolic Syndrome, and Cancer

Dr. Chuxia Deng, Chief, Mammalian Genetics Section, NIDDK, NIH

10:15 AM – 10:35AM

The Peripheral Endocannabinoid System As a Novel Therapeutic Target

Dr. George Kunos, the Scientific Director, NIAAA, NIH

10:35 AM – 10:55AM

Cancer Stem Cells and Liver Cancer

Dr. Xin Wei Wang, Chief, Section on Liver Carcinogenesis Section, NCI, NIH

Break & Refreshments

10:55 AM – 11:10AM

Session 6

Pathways to Success in China – A Bird’s-Eye View through Case Studies (Presentations and Panel Discussion)

Session Chairs: Dr. Dong Xie and Dr. Lin Sun-Hoffman

11:10 AM – 11:30AM

Patient Discovery-Challenge and Opportunity

Dr. G. Terry Sharrer, Executive Director, Medical Innovation & Transformation Institute, Inova Health System

11:30 AM – 11:50AM

Key Factors for Increasing China-US Partnering in Biotech

Ms. Linda Powers, Managing Director, Toucan Capital Corp.

11:50 AM – 12:10 PM

The NFCR-ShanghaiBio Alliance and the Tissue Bank Consortium in Asia – *Bringing non-profit and for-profit entities together to accelerate scientific progress*

Dr. Sree Kaimal, Senior Vice President, National Foundation for Cancer Research, and Dr. Jason Jin, President, ShanghaiBio Corporation

12:10 PM – 12:30 PM

Overview of the Chinese Economy and Capital Market Today

Dr. Haodong Li, Asset Manager, China Southern Fund Management Co. Ltd.

Session 7

12:30 PM – 1:30 PM

**Interactive Dialogue and Panel Discussion on Working in China and
Seeking Investment from China**

Session Chairs: Dr. Haodong Li and Dr. Guo-liang Yu

Dr. Guo-Liang Yu, Chairman and CEO, Epitomics, Inc.

Dr. Patrick Lu, President and CEO, Sirnaomics

Dr. Dajun Yang, President & CEO, Ascentage Pharma Group Corp.

Dr. Sun Lu, Executive Vice President, GeneCopoeia, Inc

Dr. Dong Xie, President and CEO, Frontier Biotechnologies Co.Ltd.

Closing Remarks: 1:30pm

Dr. Sujuan Ba, President of CBA 2010-2011